Oratray gets equity backing from Greyhill oral care fund

Oratray said Greyhill Ventures’ Oral Care Fund closed an equity investment in March 2026 as the Miami-based company advances its prefilled dental tray platform, led by a prescription fluoride tray in the FDA 510(k) pathway. The company also added a Vitamin E Wellness Tray and says it expects production by late 2026 and a commercial launch in early 2027.

Why it matters: - The investment gives Oratray backing as it pushes a prefilled dental tray platform toward regulatory clearance and commercialization. - The company is building a delivery system that could support multiple oral care products, not just one fluoride application. - The platform has already attracted reported commercial interest, which could matter once the first regulated product clears FDA review.

What happened: - Oratray said Greyhill Ventures Oral Care Fund I LP made an equity investment in the company. - The deal closed in March 2026. - Oratray is based in Delaware and develops a prefilled dental tray drug/device delivery platform for oral health. - The investment amount was not disclosed.

The details: - Oratray’s first regulated product is a prescription fluoride tray advancing through the FDA Class II 510(k) pathway under an active pre-submission. - The fluoride tray is designed to address tooth sensitivity through dentin tubule occlusion. - The fluoride tray has not been cleared by the FDA and is not available for sale in the United States. - Oratray added a second product after the investment closed: the Oratray Vitamin E Wellness Tray. - The Vitamin E Wellness Tray is a cosmetic and wellness SKU designed to support gum health, ease comfort after teeth whitening, support gum comfort after dental procedures, and promote overall oral wellness. - Oratray expects the Vitamin E Wellness Tray to enter production by the end of 2026. - Oratray targets a commercial launch for the first quarter of 2027. - The platform uses a flexible, mouthguard-shaped tray fitted with easy-to-burst gel packs that release an active formulation across the teeth and gums when the user bites down. - Oratray said it has reported an order from Teledentistry.com valued in the millions of dollars annually, with deliveries to begin after FDA 510(k) clearance. - Oratray also said it has a letter of intent from Oral Genome for the Vitamin E Wellness Tray. - The company holds granted U.S. patents covering its delivery system and has corresponding patent protection in Europe, with an international PCT filing also on file.

Between the lines: - Greyhill’s Oral Care Fund focuses on early-stage companies developing dental healthcare technologies, which fits Oratray’s platform strategy. - Greyhill Managing Partner Faizal Javer said the fund backed Oratray on the view that the same delivery format can support other actives over time. - The comments point to a broader bet on delivery innovation in oral care, where the treatment goal may be familiar but the user experience remains a barrier. - Oratray’s reported interest from distributors and its dual-product platform suggest the company is trying to build both a regulated prescription path and a wellness line.

What's next: - Oratray plans to continue the FDA 510(k) process for the fluoride tray. - The company expects the Vitamin E Wellness Tray to move into production by late 2026. - Oratray is aiming for a first-quarter 2027 commercial launch for the Wellness Tray. - Commercial deliveries tied to the fluoride tray depend on FDA 510(k) clearance.

The bottom line: - Greyhill’s investment validates Oratray’s plan to turn a single tray format into a multi-product oral care platform, but the company still needs regulatory clearance before its lead fluoride product can reach the U.S. market.